$7.42
2.49% yesterday
Nasdaq, Jun 02, 10:00 pm CET
ISIN
US30233G1004
Symbol
EYPT
Sector
Industry

EyePoint Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
6 days ago
WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate in fireside chats at the following upcoming investor conferences:
Neutral
GlobeNewsWire
7 days ago
– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest –
Neutral
GlobeNewsWire
18 days ago
WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in a...
Neutral
GlobeNewsWire
21 days ago
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming investor conferences: RBC Capital Markets Global Healthcare Conference For...
Neutral
Seeking Alpha
27 days ago
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants George Elston - Executive Vice President & Chief Financial Officer Jay Duker - President & Chief Executive Officer Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Jennifer Kim - Cantor Tessa Romero - JPMorgan Tyler Van Buren - TD Cowen Yatin Suneja - Gug...
Neutral
GlobeNewsWire
27 days ago
– Enrollment continues to exceed expectations in DURAVYU ™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $318 million of cash, cash equivalents and marketable securities as of March 31, 2025, provides cash runway in...
Neutral
GlobeNewsWire
about one month ago
WATERTOWN, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial result...
Neutral
GlobeNewsWire
about 2 months ago
WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today